PALO ALTO, California, November 23, 2021 / PRNewswire / – Genoox, a company with the world’s largest community-driven genomic data platform, announced today that its genetic and genomic data management technology will be available to clinicians and researchers at University of Washington Faculty of Medicine in St. Louis, with the aim of promoting genomics-guided precision medicine.
The Genoox platform includes the Genoox analysis engine for bioinformatic analysis of next-generation sequencing (NGS) data, along with Franklin, a genetic knowledge base powered by artificial intelligence that facilitates the comparison and interpretation of identified genetic variants from large pools. genomic data. Backed by Genoox’s technical development and support team, the platform will be customized for clinical and research workflows in University of Washington.
The Genoox Enterprise Level implementation represents a comprehensive effort to provide University of Washington with the opportunity to centralize and harmonize NGS data from clinical trials in oncology, rare and complex inherited diseases, reproductive medicine and pharmacogenetics, along with the institution’s extensive genomic research.
“Clinical genomics is advancing at an accelerated rate and we are looking at the ‘next generation’ of NGS testing, where highly curated data is integrated into test platforms and test sites in real time,” he said. Jonathan Heusel MD, PhD, Director of Clinical Genetics and Genomics at University of Washington Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine. “We will offer the Genoox platform to physicians and researchers, with the goal of identifying clinically relevant genetic alterations in many diseases and enhancing our precision medicine efforts in University of Washington and at our partner hospitals, Barnes-Jewish Hospital and St. Louis Children’s Hospital. “
According to Amir trabelsi, CEO and co-founder of Genoox, “The adoption of our technology by University of Washington will expand the use of our independent indications platform, further catalyzing our growing community of 1,700 healthcare organizations today and impacting the lives of many people who depend on precision medicine. Our growing genomics community will benefit from state-of-the-art science and a deeply committed clinical group already using NGS tests; together, we will make a significant contribution to setting new standards in genomics-driven healthcare. “
Genoox uses the power of the community to make genomic data actionable, with a mission to create the largest real-world evidence network for genomic and clinical data. Genoox’s cloud-based artificial intelligence platform connects physicians, genetic counselors, and healthcare organizations to create a network effect by sharing genetic knowledge, enabling platform users to make impactful discoveries using the tools and applications. more advanced genomics. Genoox is used by more than 1,700 healthcare organizations, hospitals and medical facilities in 44 markets around the world.